Cargando…

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial

INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Manohar, Chikka Moga Siddaiah, Nagabhushana, Mahadevappa, Karthikeyan, Vilvapathy Senguttuvan, Sanjay, Ramachandra Pudakalkatti, Kamath, Ananth Janardhan, Keshavamurthy, Ramaiah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510335/
https://www.ncbi.nlm.nih.gov/pubmed/28721281
http://dx.doi.org/10.5173/ceju.2017.924
_version_ 1783250164449804288
author Manohar, Chikka Moga Siddaiah
Nagabhushana, Mahadevappa
Karthikeyan, Vilvapathy Senguttuvan
Sanjay, Ramachandra Pudakalkatti
Kamath, Ananth Janardhan
Keshavamurthy, Ramaiah
author_facet Manohar, Chikka Moga Siddaiah
Nagabhushana, Mahadevappa
Karthikeyan, Vilvapathy Senguttuvan
Sanjay, Ramachandra Pudakalkatti
Kamath, Ananth Janardhan
Keshavamurthy, Ramaiah
author_sort Manohar, Chikka Moga Siddaiah
collection PubMed
description INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MATERIAL AND METHODS: Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0.4 mg tamsulosin (group T), 10 mg alfuzosin (group A) or a 8 mg silodosin (group S) by double-blind randomization. All patients were assessed for improvements and post-void residual urine (PVR) and for adverse drug events (ADE). RESULTS: IPSS showed significant improvement in Group S at the first week (11.7 ±4.18, p = 0.027) and at 3 months (7.97 ±3.84, p = 0.020). QOL showed significant improvement at 1 (2.2 ±0.76, p = 0.020), 4 (1.47 ±0.63, p <0.001) and 12 (1.2 ±0.66, p <0.001) weeks in Group S. The mean Qmax improvement was the maximum (13.76 ±2.44, p = 0.028) in Group S at 1 week. Reduction in PVR was the maximum in Group S, but it was not statistically significant. Adverse drug events (ADE) were observed in 20.07% (54/269) patients and distribution was similar in the three groups with decreasing incidence with progression of time. CONCLUSIONS: Silodosin is the most efficacious AB with rapid onset of action. Silodosin also improves the quality of life in patients with LUTS due to BPH and objectively improves maximum flow rate. However, silodosin has more adverse events when compared to tamsulosin and alfuzosin.
format Online
Article
Text
id pubmed-5510335
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Polish Urological Association
record_format MEDLINE/PubMed
spelling pubmed-55103352017-07-18 Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial Manohar, Chikka Moga Siddaiah Nagabhushana, Mahadevappa Karthikeyan, Vilvapathy Senguttuvan Sanjay, Ramachandra Pudakalkatti Kamath, Ananth Janardhan Keshavamurthy, Ramaiah Cent European J Urol Original Paper INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MATERIAL AND METHODS: Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0.4 mg tamsulosin (group T), 10 mg alfuzosin (group A) or a 8 mg silodosin (group S) by double-blind randomization. All patients were assessed for improvements and post-void residual urine (PVR) and for adverse drug events (ADE). RESULTS: IPSS showed significant improvement in Group S at the first week (11.7 ±4.18, p = 0.027) and at 3 months (7.97 ±3.84, p = 0.020). QOL showed significant improvement at 1 (2.2 ±0.76, p = 0.020), 4 (1.47 ±0.63, p <0.001) and 12 (1.2 ±0.66, p <0.001) weeks in Group S. The mean Qmax improvement was the maximum (13.76 ±2.44, p = 0.028) in Group S at 1 week. Reduction in PVR was the maximum in Group S, but it was not statistically significant. Adverse drug events (ADE) were observed in 20.07% (54/269) patients and distribution was similar in the three groups with decreasing incidence with progression of time. CONCLUSIONS: Silodosin is the most efficacious AB with rapid onset of action. Silodosin also improves the quality of life in patients with LUTS due to BPH and objectively improves maximum flow rate. However, silodosin has more adverse events when compared to tamsulosin and alfuzosin. Polish Urological Association 2017-06-07 2017-06-30 /pmc/articles/PMC5510335/ /pubmed/28721281 http://dx.doi.org/10.5173/ceju.2017.924 Text en Copyright by Polish Urological Association http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Manohar, Chikka Moga Siddaiah
Nagabhushana, Mahadevappa
Karthikeyan, Vilvapathy Senguttuvan
Sanjay, Ramachandra Pudakalkatti
Kamath, Ananth Janardhan
Keshavamurthy, Ramaiah
Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title_full Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title_fullStr Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title_full_unstemmed Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title_short Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double-blind randomized trial
title_sort safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for luts in bph – a double-blind randomized trial
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510335/
https://www.ncbi.nlm.nih.gov/pubmed/28721281
http://dx.doi.org/10.5173/ceju.2017.924
work_keys_str_mv AT manoharchikkamogasiddaiah safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial
AT nagabhushanamahadevappa safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial
AT karthikeyanvilvapathysenguttuvan safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial
AT sanjayramachandrapudakalkatti safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial
AT kamathananthjanardhan safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial
AT keshavamurthyramaiah safetyandefficacyoftamsulosinalfuzosinorsilodosinasmonotherapyforlutsinbphadoubleblindrandomizedtrial